Next-Generation Contraceptives Market

Global and Regional Gender, Offering, End User Analysis and Forecasts, 2024-2033

The global next-generation contraceptives market report provides a comprehensive analysis of the industry, offering insights into key market trends, growth drivers, challenges, and opportunities, and forecasts that a decision-maker can take advantage of.

The market study encompasses a detailed examination of various next-generation contraceptives including technological advancements, and market dynamics. It explores the market based on segmentations such as by gender, and by offering and by distribution channel and highlights the competitive landscape, profiling key players and their strategies for market expansion. The report delves into regional segmentation, evaluating market performance across different geographical areas. Additionally, it discusses the impact of macroeconomic factors on market growth and explores potential investment opportunities for stakeholders.

With a focus on fostering a deep understanding of market dynamics, the report serves as a valuable resource for businesses, investors, and industry participants seeking strategic insights into the evolving global next-generation contraceptives market.

Key Questions Answered:

  • What are the major market drivers, challenges, and opportunities in the global next-generation contraceptives market and their case studies?
  • How will the next-generation contraceptives market evolve and what is its scope in the future?
  • What is the market share of the leading segments and sub-segments of the global next-generation contraceptives market?
  • How will each segment of the global next-generation contraceptives market grow during the forecast period?
  • What are the key developmental strategies implemented by the key players to stand out in this market?

Companies Featured

  • AbbVie
  • Bayer Corporation
  • Cooper Surgical, Inc.
  • Church & Dwight Co, Inc.
  • Merck & Co Inc.
  • Pfizer
  • Reckitt Benckiser Group Plc
  • Teva Pharmaceuticals Industries Ltd.
  • The Female Health Company/Veru Inc.
  • Afaxys, Inc
  • Aditxt
  • Dare Bioscience, Inc
  • TherapeuticsMD, Inc

Key Topics Covered:

1 Markets: Industry Outlook

1.1 Trends: Current and Future Impact Assessment

1.2 Supply Chain Overview

1.2.1 Value chain Analysis

1.2.2 Market Map

1.3 R&D Review

1.3.1 Patent Filing Trend by Country, by Company

1.4 Regulatory Landscape

1.5 Market Dynamics Overview

1.5.1 Market Drivers

1.5.2 Market Restraints

1.5.3 Market Opportunities

2 Next-Generation Contraceptives Market by Application

2.1 Application Segmentation

2.2 Application Summary

2.3 Global Next-Generation Contraceptives Market, by Gender

2.3.1 Male

2.3.2 Female

2.4 Global Next-Generation Contraceptives Market, by End User

2.4.1 Hospital Pharmacies

2.4.2 Retail Pharmacies

2.4.3 Online Channels

2.4.4 Others

3 Next-Generation Contraceptives Market by Product Type

3.1 Product Segmentation

3.2 Product Summary

3.3 Global Next-Generation Contraceptives Market, by Offering

3.3.1 Drugs

3.3.1.1 Contraceptive Pills

3.3.1.2 Injectables

3.3.1.3 Patches

3.3.1.4 Others

3.3.2 Devices

3.3.2.1 Condoms

3.3.2.2 Vaginal Rings

3.3.2.3 Intra-uterine Devices

3.3.2.4 Others

4 Next-Generation Contraceptives Market by Region

4.1 Regional Summary

4.2 Drivers and Restraints as you go along.

4.3 North America

4.3.1 Markets

4.3.1.1 Key Market Participants in North America

4.3.1.2 Business Drivers

4.3.1.3 Business Challenges

4.3.2 North America Next Generation Contraceptives Market, by End User

4.3.3 North America by Country

4.3.3.1 U.S.

4.3.3.2 Canada

4.4 Europe

4.5 Asia-Pacific

4.6 Latin America

4.7 Middle East and Africa

5 Markets – Competitive Landscape & Company Profiles

5.1 Competitive Landscape

5.2 Company Profiles

5.2.1 Company Overview

5.2.2 Top Products / Product Portfolio

5.2.3 Top Competitors

5.2.4 Target Customers /End-Users

5.2.5 Key Personnel

5.2.6 Analyst View

For more information about this report visit https://www.researchandmarkets.com/r/gv583m

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”